AstraZeneca reports Phase 3 success for eneboparatide in hypoparathyroidism following $1.05B Amolyt Pharma acquisition. Drug ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetesCATT1 Phase 3 trial expected to resume following ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

AbbVie (ABBV) announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE in women ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

They are conducting phase 3 trials for the combination drug 'CagriSema,' which consists of cagrilintide and semaglutide, the active ingredient in the GLP-1 series Wigobi. However, while the weight ...

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...